CSF1R and ovarian carcinoma: The usefulness of targeting the binding of CSF-1 and CSF1R was shown in a preclinical study, where a mouse model of ovarian cancer that had been intravenously administered a CSF-1R inhibitor (BLZ945) exhibited a decrease and an increase in TAM cells and CD8+ T, respectively (45).